Foghorn Therapeutics Unveils Clinical Pipeline Progress
Express News | Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors
Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions
Express News | Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
Press Release: Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore
Foghorn Therapeutics to Participate in the BMO Oncology Summit
Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Foghorn Therapeutics: Holding for FHD-286 Clinical Trial Outcomes and Financial Position Analysis
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
Express News | Deerfield Mgmt, L.p Reports 5.31% Passive Stake in Foghorn Therapeutics as of Sept 13 - SEC Filing
Foghorn Therapeutics Executive Sells Over $107k in Company Stock
Press Release: Foghorn Therapeutics Strengthens Leadership Team With Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
Jefferies Initiates Foghorn Therapeutics(FHTX.US) With Buy Rating, Announces Target Price $18
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases Under Strategic Partnership With Pfizer
What Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Gain Is Not Telling You